Cargando…
The small molecule inhibitor anle145c thermodynamically traps human islet amyloid peptide in the form of non-cytotoxic oligomers
Type 2 diabetes (T2DM) is associated with aggregation of the human islet amyloid polypeptide (hIAPP) into cytotoxic amyloid species. Here we tested the effect of a diphenylpyrazole (DPP)-derived small molecule inhibitor, anle145c, on cytotoxicity and on aggregation properties of hIAPP. We demonstrat...
Autores principales: | Saravanan, Manikam S., Ryazanov, Sergey, Leonov, Andrei, Nicolai, Janine, Praest, Patrique, Giese, Armin, Winter, Roland, Khemtemourian, Lucie, Griesinger, Christian, Killian, J. Antoinette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911113/ https://www.ncbi.nlm.nih.gov/pubmed/31836748 http://dx.doi.org/10.1038/s41598-019-54919-z |
Ejemplares similares
-
The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset
por: Levin, Johannes, et al.
Publicado: (2014) -
Anle138b modulates α‐synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy
por: Heras‐Garvin, Antonio, et al.
Publicado: (2018) -
Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy
por: Fellner, Lisa, et al.
Publicado: (2016) -
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease
por: Wagner, Jens, et al.
Publicado: (2013) -
The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils
por: Antonschmidt, Leif, et al.
Publicado: (2022)